Key Points
- Philip Nickson sold 5,845 shares on April 9 at $17.69 for $103,398.05, cutting his stake by 9.61% to 55,000 shares valued at about $972,950.
- Monte Rosa missed expectations in its March 17 quarter, reporting EPS of -$0.55 vs a -$0.45 consensus and revenue of $2.78M vs a $17.09M estimate, with negative margins and ROE.
- Analysts collectively rate the stock a “Moderate Buy” (six Buys, one Hold, one Sell) with an average price target of $32.80, and institutional investors own roughly 79.96% of the company.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) insider Philip Nickson sold 5,845 shares of Monte Rosa Therapeutics stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $17.69, for a total transaction of $103,398.05. Following the transaction, the insider directly owned 55,000 shares of the company's stock, valued at $972,950. The trade was a 9.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Monte Rosa Therapeutics Stock Down 3.2%
NASDAQ GLUE opened at $17.48 on Friday. The company has a fifty day moving average of $17.63 and a two-hundred day moving average of $15.97. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -38.00 and a beta of 1.63. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.51 and a 52 week high of $25.77.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last released its earnings results on Tuesday, March 17th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Monte Rosa Therapeutics had a negative return on equity of 15.12% and a negative net margin of 31.23%.The business had revenue of $2.78 million for the quarter, compared to the consensus estimate of $17.09 million. Equities research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.
Wall Street Analyst Weigh In
GLUE has been the subject of several research analyst reports. Wedbush reiterated an "outperform" rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Zacks Research downgraded Monte Rosa Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 4th. Jefferies Financial Group reiterated a "buy" rating and set a $31.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Piper Sandler reiterated an "overweight" rating and set a $37.00 target price (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $32.80.
Check Out Our Latest Stock Report on GLUE
Hedge Funds Weigh In On Monte Rosa Therapeutics
Several institutional investors have recently made changes to their positions in the company. Seven Fleet Capital Management LP purchased a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at $63,000. Virtu Financial LLC increased its stake in shares of Monte Rosa Therapeutics by 56.6% during the fourth quarter. Virtu Financial LLC now owns 18,717 shares of the company's stock valued at $293,000 after buying an additional 6,765 shares during the period. Invesco Ltd. increased its stake in shares of Monte Rosa Therapeutics by 270.0% during the fourth quarter. Invesco Ltd. now owns 362,213 shares of the company's stock valued at $5,680,000 after buying an additional 264,315 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at $172,000. Finally, Empowered Funds LLC increased its stake in shares of Monte Rosa Therapeutics by 218.0% during the fourth quarter. Empowered Funds LLC now owns 278,077 shares of the company's stock valued at $4,360,000 after buying an additional 190,627 shares during the period. Hedge funds and other institutional investors own 79.96% of the company's stock.
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.
The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
